Last checked at 16 Mar 2022 07:00
16 March 2022
SkinBioTherapeutics plc
Notice of Results
SkinBioTherapeutics plc's (AIM: SBTX or the "Company") interim financial results for the six months to 31 December 2021 will be released on Tuesday 29 March 2022.
-Ends-
For more information please contact:
SkinBioTherapeutics plc Stuart J. Ashman, CEO Doug Quinn, CFO | Tel: +44 (0) 161 468 2760 |
Cenkos Securities Plc (Nominated Adviser & Broker) Giles Balleny, Max Gould (Corporate Finance) Michael Johnson, Dale Bellis (Sales) | Tel: +44 (0) 20 7397 8900 |
Instinctif Partners (financial press) Melanie Toyne-Sewell / Nathan Billis | Tel: +44 (0) 20 7457 2020 SkinBio@instinctif.com |
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.
The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AsixBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis was launched on 29 October - World Psoriasis Day.
The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit: www.skinbiotix.com.